EA-5

N/A

Report date: 2026/04/29 10:12:44

Base Information

Drug NameEA-5
Drug Alias NameEA5EA-5
ClassificationBiologics
Mechanisms of ActionComplement C5 inhibitors
TargetsComplement C5
Therapy Area/IndicationsAntiphospholipid SyndromeThrombotic MicroangiopathiesHemoglobinuria, Paroxysmal +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesShandong Lanyi Pharmaceutical Technology Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesShandong Lanyi Pharmaceutical Technology Co LtdSuzhou Bowei Biotechnology Co LtdShanghai Lanyi Pharmaceutical Technology Co Ltd
Inactive CompaniesN/A
Active IndicationsAntiphospholipid SyndromeThrombotic MicroangiopathiesHemoglobinuria, Paroxysmal +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A